权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Study of new immunosuppressive strategy and kinetics for ABO incompatible transplantation

ABO血型不合移植免疫抑制新策略及动力学研究

基本信息

批准号：
18591401
负责人：
KAWAGISHI Naoki
金额：
$ 2.43万
依托单位：
Tohoku University
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2006
资助国家：
日本
起止时间：
2006 至 2007
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18591401/
关键词：
incompatible liver transplantation rejection kidney transplantation 腎臓移植

项目摘要

In Japan, the shortage of grafts has encouraged us to perform living donor liver transplantation (LDLT) across the ABO blood barrier. To decide the treatment for an ABO-I recipient, the amount of anti-AB antibody (Ab) is very important. At present, the quantity of anti-AB Ab is represented by the agglutination titer. We developed an enzyme linked immunosorbent assay (ELISA) to measure anti-AB Ab, and assessed its usefulness in clinical practice in this study.In this report, we describe a novel ELISA we have developed to measure anti-histo-blood group Ab in patients subjected to LDLT, which uses synthetic carbohydrate blood group antigens. We assessed the correlation between optical density (O.D.) determined by ELISA and agglutination titers, and considered the possibility of using ELISA in clinical cases. (Tohoku Journal of Experimental Medicine, 211; 359-367,2007) And'' in another study we experienced 9 recipients who underwent apheresis to eliminate allogeneic antibodies, out of 101 LDLT patients. We focused d on the indication and the efficacy of apheresis as extracorporeal immunomodulation for the elimination of antibodies in patients undergoing LDLT. The long-term follow-up was also investigated. (Therapeutic Apheresis and Dialysis; 11(5):319-32.4, 2007) In conclusion, our ELISA method is useful to detect changes in individually anti-A/B Ab and may have the possibility of using ELISA in clinical cases.

在日本，移植物的短缺鼓励我们进行跨越ABO血液屏障的活体肝移植（LDLT）。为了决定对ABO-I受体的治疗，抗AB抗体（Ab）的量是非常重要的。目前，抗AB抗体的量用凝集效价表示。我们开发了一种酶联免疫吸附试验（ELISA）来测量抗AB抗体，并评估其在临床实践中的实用性在本study.In这份报告中，我们描述了一种新的ELISA，我们已经开发出测量抗组织血型抗体的患者进行LDLT，它使用合成的碳水化合物血型抗原。我们评估了光密度（O.D.）用ELISA法和凝集效价测定，并探讨了ELISA法用于临床的可能性。（Tohoku Journal of Experimental Medicine，211; 359- 367，2007）在另一项研究中，我们在101名LDLT患者中经历了9名接受者，他们接受了单采术以消除同种抗体。我们重点研究了单采术作为体外免疫调节用于消除接受LDLT患者中抗体的适应症和有效性。并进行了长期随访。（Therapeutic Apheresis and Dialysis; 11（5）：319-32.4，2007）总之，我们的ELISA方法可用于检测单独抗A/B Ab的变化，并且可能具有在临床病例中使用ELISA的可能性。